bactroban ointment 5g
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 2 | $27.59 | $55.18 (0%) | 🛒 Add to cart |
| 3 | $25.08 | $82.78 $75.25 (9%) | 🛒 Add to cart |
| 4 | $23.83 | $110.37 $95.32 (14%) | 🛒 Add to cart |
| 5 | $23.08 | $137.96 $115.39 (16%) | 🛒 Add to cart |
| 6 | $22.58 | $165.55 $135.45 (18%) | 🛒 Add to cart |
| 7 | $22.22 | $193.14 $155.52 (19%) | 🛒 Add to cart |
| 8 | $21.95 | $220.74 $175.59 (20%) | 🛒 Add to cart |
| 9 | $21.18 | $248.33 $190.64 (23%) | 🛒 Add to cart |
| 10 | $20.07
Best per tube | $275.92 $200.67 (27%) | 🛒 Add to cart |
Synonyms | |||
Bactroban Ointment 5g represents a cornerstone in topical antimicrobial therapy, specifically mupirocin calcium 2% w/w in a polyethylene glycol base. This prescription medication occupies a unique niche in dermatological and infectious disease practice due to its targeted mechanism against gram-positive bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA). The 5g tube size provides practical treatment duration for localized skin infections while minimizing waste.
Bactroban Ointment: Targeted Antibacterial Action for Skin Infections - Evidence-Based Review
1. Introduction: What is Bactroban Ointment? Its Role in Modern Medicine
Bactroban Ointment contains mupirocin calcium as the active pharmaceutical ingredient, formulated specifically for topical administration. Unlike systemic antibiotics that distribute throughout the body, this ointment delivers high concentrations directly to the site of infection while minimizing systemic exposure. What is Bactroban used for? Primarily, it addresses superficial skin infections caused by susceptible organisms, with particular importance in decolonization protocols for MRSA carriers. The medical applications extend beyond simple impetigo to include secondary infected traumatic skin lesions and eradication of nasal colonization by Staphylococcus aureus. The significance of Bactroban Ointment in modern therapeutic arsenals cannot be overstated, especially as antimicrobial resistance continues to challenge conventional treatment approaches.
2. Key Components and Bioavailability of Bactroban Ointment
The composition of Bactroban Ointment reflects careful pharmaceutical design. Mupirocin calcium, the active component, exists at 2% concentration (equivalent to 20 mg mupirocin per gram of ointment). The polyethylene glycol base deserves particular attention - it’s not merely an inert vehicle but actively contributes to drug delivery by maintaining hydration at the application site and facilitating penetration into skin layers.
Bioavailability of topical mupirocin demonstrates interesting characteristics. When applied to intact skin, systemic absorption remains negligible, with studies showing undetectable serum levels in most patients. However, application to damaged skin or large body surface areas can result in minimal systemic absorption, though this rarely reaches clinically significant levels. The release form ensures sustained local concentration far exceeding the minimum inhibitory concentrations for target organisms.
The specific formulation matters tremendously - the ointment base protects the labile mupirocin molecule from degradation while creating an optimal environment for antibacterial activity. This explains why alternative vehicles or concentrations may not provide equivalent efficacy.
3. Mechanism of Action of Bactroban Ointment: Scientific Substantiation
Understanding how Bactroban works requires examining its unique biochemical targeting. Mupirocin specifically inhibits bacterial isoleucyl-tRNA synthetase, an enzyme essential for protein synthesis. This mechanism differs fundamentally from beta-lactams, quinolones, or macrolides, explaining the lack of cross-resistance with these classes.
The effects on the body are predominantly local, with minimal systemic impact when used appropriately. Scientific research has elucidated that mupirocin binds reversibly to the bacterial enzyme, preventing incorporation of isoleucine into protein chains. This targeted action halts bacterial replication without affecting human protein synthesis, as mammalian isoleucyl-tRNA synthetase remains insensitive to mupirocin’s effects.
Think of it as a precision strike against bacterial infrastructure rather than blanket bombardment. This specificity explains the favorable safety profile but also highlights the importance of appropriate application - the antibiotic must reach the target organisms in sufficient concentration.
4. Indications for Use: What is Bactroban Ointment Effective For?
Bactroban Ointment for Impetigo
Primary treatment of impetigo caused by Staphylococcus aureus and Streptococcus pyogenes represents the most common indication. The ointment formulation particularly suits the crusted lesions characteristic of bullous and non-bullous impetigo, with clinical trials demonstrating eradication rates exceeding 85-90% when used as directed.
Bactroban Ointment for Secondary Infected Skin Lesions
Traumatic skin lesions, surgical wounds, or dermatological conditions like eczema that become secondarily infected with susceptible organisms respond well to targeted Bactroban therapy. The treatment approach here focuses on eliminating the bacterial component while addressing the underlying condition.
Bactroban Ointment for MRSA Decolonization
Perhaps the most critical application involves nasal decolonization of MRSA carriers. The intranasal application (though technically off-label for the skin ointment, with nasal formulation preferred) has demonstrated significant reduction in MRSA transmission risk in healthcare settings and during surgical procedures.
Bactroban for Prevention of Recurrent Skin Infections
Patients with recurrent furunculosis or other staphylococcal skin infections may benefit from eradication of nasal carriage, as the nares often serve as the reservoir for autoinoculation.
5. Instructions for Use: Dosage and Course of Administration
Clear instructions for use of Bactroban Ointment optimize therapeutic outcomes while minimizing resistance development. The standard approach involves:
| Indication | Frequency | Duration | Application Notes |
|---|---|---|---|
| Impetigo | 3 times daily | 7-10 days | Apply small amount, cover with gauze if desired |
| Secondary infections | 2-3 times daily | 7-14 days | Clean area first, apply thin layer |
| MRSA decolonization | 2 times daily | 5-10 days | Apply to inner nostrils (nasal formulation preferred) |
Dosage considerations emphasize that a pea-sized amount typically suffices for a 2-inch diameter area. The course of administration should complete fully even if symptoms improve earlier, though treatment beyond 10 days generally isn’t recommended for skin applications due to resistance concerns.
Side effects remain predominantly local - application site reactions including burning, stinging, or itching occur in approximately 3% of patients. Systemic side effects are exceptionally rare with appropriate use.
6. Contraindications and Drug Interactions with Bactroban Ointment
Contraindications for Bactroban Ointment focus primarily on hypersensitivity to mupirocin or any components of the polyethylene glycol base. Patients with documented allergic reactions should avoid this medication.
Important safety considerations include:
Pregnancy and lactation: Category B classification indicates no demonstrated risk in animal studies, but human data remains limited. Use when clearly needed, weighing potential benefits against theoretical risks.
Pediatric use: Approved for children 2 months and older, though younger infants require careful monitoring.
Renal impairment: Generally safe topically, but caution with extensive application to compromised skin barriers in severe renal dysfunction.
Interactions with other drugs are minimal due to negligible systemic absorption. However, concurrent use with other topical products on the same site may alter absorption characteristics or cause physical incompatibility. Applying other topical medications within 30 minutes of Bactroban isn’t recommended.
7. Clinical Studies and Evidence Base for Bactroban Ointment
The clinical studies supporting Bactroban Ointment span decades, with the evidence base continually expanding. A 2018 systematic review in JAMA Dermatology analyzed 27 randomized controlled trials, confirming superiority to placebo and non-inferiority to several oral antibiotics for impetigo treatment.
Scientific evidence specifically regarding MRSA decolonization comes from landmark studies including the REDUCE MRSA trial published in NEJM, which demonstrated significant reduction in ICU bloodstream infections with universal decolonization protocols including intranasal mupirocin.
Effectiveness metrics show clinical cure rates of 87-92% for primary skin infections, with microbiological eradication slightly higher. Physician reviews consistently note the importance of Bactroban as a resistance-sparing option when systemic antibiotics aren’t necessary.
Recent real-world evidence from dermatology practices indicates that appropriate use of topical mupirocin can reduce oral antibiotic prescriptions by 30-40% for uncomplicated skin infections, representing an important antimicrobial stewardship achievement.
8. Comparing Bactroban Ointment with Similar Products and Choosing Quality
When considering Bactroban similar products, several factors distinguish mupirocin from alternatives:
Versus bacitracin: Mupirocin demonstrates superior activity against S. aureus and specific anti-MRSA capability lacking in bacitracin.
Versus fusidic acid: While both target gram-positive organisms, the mechanisms differ significantly, and regional resistance patterns often dictate preference.
Versus retapamulin: Newer agent with similar spectrum but different resistance profile, often reserved for cases with suspected mupirocin resistance.
Which Bactroban is better? The question actually involves formulation selection - the calcium salt in the ointment provides greater stability than the free acid, while the nasal formulation offers specialized vehicle for intranasal use.
How to choose involves considering local resistance patterns, specific indication, patient factors, and cost considerations. The 5g tube typically provides adequate medication for a standard treatment course without significant waste.
9. Frequently Asked Questions (FAQ) about Bactroban Ointment
What is the recommended course of Bactroban Ointment to achieve results?
Most skin infections require 7-10 days of treatment, applied 2-3 times daily. MRSA decolonization typically uses 5-day courses, though protocols vary.
Can Bactroban Ointment be combined with corticosteroid creams?
Sequential application is acceptable (wait 30 minutes between products), but simultaneous mixing in the hand isn’t recommended as it may alter release characteristics.
Is Bactroban Ointment safe for diabetic patients with skin infections?
Generally yes, though diabetic patients require closer monitoring for treatment response and potential complications.
How quickly does Bactroban Ointment work?
Clinical improvement typically begins within 2-3 days, with significant resolution by day 5 in responsive infections.
Can Bactroban Ointment be used for acne?
Not recommended - the spectrum doesn’t target Cutibacterium acnes effectively, and the ointment base may exacerbate acneiform eruptions.
10. Conclusion: Validity of Bactroban Ointment Use in Clinical Practice
The risk-benefit profile firmly supports Bactroban Ointment’s position in therapeutic hierarchies for superficial skin infections. The targeted antibacterial action, favorable safety profile, and resistance-sparing potential make it particularly valuable in an era of escalating antimicrobial resistance. For appropriate indications - primarily impetigo, secondary infected skin lesions, and MRSA decolonization - the evidence base substantiates its role as first-line topical therapy.
I remember when we first started using mupirocin back in the late 90s - we were skeptical about another topical antibiotic, honestly. The pharmaceutical rep kept emphasizing this unique mechanism, but we’d heard that before. Then I had this patient, Miriam, 68-year-old with recurrent furuncles for literally years. Oral antibiotics would clear them temporarily, but they always came back. Her cultures showed MSSA, sensitive to everything, but the infections kept recurring.
We decided to try something different - treat her nasal carriage with mupirocin ointment twice daily for 5 days, even though the nasal formulation wasn’t available yet. Honestly, half the team thought it was pointless - “If systemics aren’t working, how will topical nasal treatment help?” But three months later, Miriam came back tearfully happy - first time in years without new boils. That case completely changed my perspective on reservoir eradication.
The development team actually struggled initially with stability issues - the original compound degraded too quickly. I spoke with one of the formulation scientists at a conference years later, and he mentioned they nearly abandoned the project until switching to the calcium salt. There were internal disagreements about whether to pursue the nasal formulation or focus solely on skin applications - some argued the market wasn’t big enough to justify the development costs.
We’ve learned some hard lessons since then though. The resistance patterns have shifted concerningly - when I started, high-level mupirocin resistance was rare, now we see it in maybe 15% of hospital MRSA isolates in our area. That’s why we’re much more restrictive now about duration and indications. I had a patient last year, construction worker with chronic folliculitis, who’d been using leftover mupirocin for every little skin irritation for months - cultured high-level resistant Staph. Had to use linezolid, which felt like overkill but we had limited options.
The unexpected finding for me has been how important the vehicle really is - we tried compounding mupirocin in different bases for a patient with PEG allergy, and the efficacy dropped noticeably. The pharmaceutical science matters more than we sometimes acknowledge.
Long-term follow-up on some of our pediatric impetigo patients shows interesting patterns too - the kids treated appropriately with mupirocin seem less likely to develop recurrent infections compared to those who received multiple courses of oral antibiotics. One mother told me last month, “Since we used that ointment when Sarah had the school sores last year, she hasn’t had any skin problems at all - usually she gets them every winter.”
The real clinical experience has taught me that Bactroban works best when we respect its limitations and use it precisely - not as a universal solution for every skin problem, but as a targeted tool for specific situations. That balance between accessibility and appropriate use remains challenging in daily practice.